← DPP-4 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2017

Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.

Takashi Kadowaki et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT02354235. Its numbers are set against the trial’s posted results below.

  • Teneligliptin 20 mg plus canagliflozin 100 mg (T+C)looks good hereLower HbA1c change from baseline to week 24, no range given.No ranges given.

What the trial testedas reported · 138 people · 2017

No range given

Reported lower HbA1c change from baseline to week 24, no range given

Doesn’t vote: same as the registry's posted result, which counts instead

−0.88percentage points

teneligliptin 20 mg plus canagliflozin 100 mg (T+C) vs teneligliptin 20 mg plus placebo (T+P)

As reported

difference −0.88 %, no interval

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −0.88Posted, primary outcome difference −0.88 (−1.15 to −0.60), p <0.001Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)

Who was studied, and how

138people with obesity, in this paper

The trial randomly assignedassigned by chance

teneligliptin 20 mg plus canagliflozin 100 mg (T+C)
teneligliptin 20 mg plus placebo (T+P)

Reported lower HbA1c change from baseline to week 24, no range given−0.88

randomised

the abstract, start to end

… change from baseline to week 24 was -0.88% (least-squares mean, …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HbA1c change from baseline to week 24teneligliptin 20 mg plus canagliflozin 100 mg (T+C) vs teneligliptin 20 mg plus placebo (T+P)
−0.88
SGLT2 inhibitorsDPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

41 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT02354235phase 3138 enrolled2015this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 28177187